Alba Therapeutics Corporation announces that it has completed patient enrollment and dosing in the Phase II clinical trial of drug AT-1001 for the treatment of celiac disease

BALTIMORE, Maryland 03/08/2007 – Alba Therapeutics Corporation today announced that it has completed patient enrollment and dosing in the Phase

read more